Baxter International Inc. Stock Mexican S.E.

Equities

BAX *

US0718131099

Medical Equipment, Supplies & Distribution

End-of-day quote Mexican S.E. 18:00:00 2024-05-13 EDT 5-day change 1st Jan Change
596.8 MXN -0.50% Intraday chart for Baxter International Inc. 0.00% -20.43%

Financials

Sales 2024 * 15.11B 252B 20.6B Sales 2025 * 15.66B 261B 21.35B Capitalization 17.27B 288B 23.55B
Net income 2024 * 703M 11.73B 958M Net income 2025 * 950M 15.86B 1.3B EV / Sales 2024 * 1.79 x
Net Debt 2024 * 9.7B 162B 13.23B Net Debt 2025 * 8.8B 147B 12B EV / Sales 2025 * 1.67 x
P/E ratio 2024 *
18.4 x
P/E ratio 2025 *
15.1 x
Employees 60,000
Yield 2024 *
3.52%
Yield 2025 *
3.65%
Free-Float 74.27%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.50%
Current month-13.18%
1 month-13.18%
3 months-14.57%
6 months-20.43%
Current year-20.43%
More quotes
1 month
596.75
Extreme 596.75
600.96
Current year
596.75
Extreme 596.75
698.49
1 year
596.75
Extreme 596.75
820.00
3 years
596.75
Extreme 596.75
1 778.80
5 years
596.75
Extreme 596.75
2 110.37
10 years
591.34
Extreme 591.34
2 110.37
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 15-09-30
Director of Finance/CFO 54 23-10-17
Chief Tech/Sci/R&D Officer - 16-12-31
Members of the board TitleAgeSince
Director/Board Member 73 17-02-05
Director/Board Member 64 22-05-09
Director/Board Member 64 19-02-17
More insiders
Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows: - medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.); - kidney dialysis drugs and equipment (30.1%); - systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.; - other (20.1%). Export accounts for 52.7% of net sales.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
33.9 USD
Average target price
46.07 USD
Spread / Average Target
+35.89%
Consensus